Close Menu

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte on Monday reported a 13 percent increase in its fourth quarter net loss as higher personnel-related spending pushed up overall costs.

For the three-month period ended December 31, OncoCyte's net loss rose to $4.5 million, or $.11 per share, versus $4.0 million, or $.13 per share, in the same period the year before.

The Alameda, California-based company did not generate any revenue in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.